Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacovigilance Study to Evaluate Safety of AVODART (Dutasteride) Administration 0,5 mg Once Daily, for 52 Weeks, in Subjects With Benign Prostate Hyperplasia

NCT00593593 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00593593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00593593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacovigilance Study to Evaluate Safety of AVODART (Dutasteride) Administration 0,5 mg Once Daily, for 52 Weeks, in Subjects With Benign Prostate Hyperplasia
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
December 31, 2004
Completion date
Not reported
Enrollment
1,000
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia